Invariant natural killer T cells and immunotherapy of cancer

Clinical Immunology

Volumn 129, Issue 2, 2008, Pages 182-194

  Molling, Johan W ^a   Moreno, María ^a   van der Vliet, Hans J J ^a   van den Eertwegh, Alfons J M ^a   Scheper, Rik J ^a   von Blomberg, B Mary E ^a   Bontkes, Hetty J ^a  

^a VUmc Institute for Cancer and Immunology V ICI   (Netherlands)

Author keywords

Cancer; Immune surveillance; Immunotherapy; iNKT cell; Prognosis

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 2; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARCINOMA; CELL FUNCTION; CELL THERAPY; CELL TRANSFER; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DENDRITIC CELL; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MELANOMA; METASTASIS; MYELOMA; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANIMALS; ANTIGENS, CD1; CELL LINE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS;

EID: 53749092033     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.07.025     Document Type: Short Survey

References (133)

1. Penn I. Tumors of the immunocompromised patient. Annu. Rev. Med. 39 (1988) 63-73
2. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16 1 (2006) 3-15
3. Young M.R. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 28 5 (2006) 462-470
4. Whiteside T.L. The role of immune cells in the tumor microenvironment. Cancer Treat. Res. 130 (2006) 103-124
5. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol. Today 21 11 (2000) 573-583
6. Porcelli S., Yockey C.E., Brenner M.B., and Balk S.P. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J. Exp. Med. 178 1 (1993) 1-16
7. Spada F.M., Koezuka Y., and Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188 8 (1998) 1529-1534
8. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 5343 (1997) 1626-1629
9. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 5702 (2004) 1786-1789
10. Kinjo Y., Wu D., Kim G., Xing G.W., Poles M.A., Ho D.D., et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 7032 (2005) 520-525
11. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu III C., Zhou D., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 7032 (2005) 525-529
12. Speak A.O., Salio M., Neville D.C., Fontaine J., Priestman D.A., Platt N., et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl. Acad. Sci. U. S. A. 104 14 (2007) 5971-5976
13. Porubsky S., Speak A.O., Luckow B., Cerundolo V., Platt F.M., and Grone H.J. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. U. S. A. 104 14 (2007) 5977-5982
14. Brigl M., Bry L., Kent S.C., Gumperz J.E., and Brenner M.B. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4 12 (2003) 1230-1237
15. van der Vliet H.J., Molling J.W., von Blomberg B.M., Nishi N., Kolgen W., van den Eertwegh A.J., et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin. Immunol. 112 1 (2004) 8-23
16. von Herrath M.G., Fujinami R.S., and Whitton J.L. Microorganisms and autoimmunity: making the barren field fertile?. Nat. Rev. Microbiol. 1 2 (2003) 151-157
17. Gumperz J.E., Miyake S., Yamamura T., and Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195 5 (2002) 625-636
18. Kim C.H., Butcher E.C., and Johnston B. Distinct subsets of human Valpha24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol. 23 11 (2002) 516-519
19. Lee P.T., Benlagha K., Teyton L., and Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 195 5 (2002) 637-641
20. Seino K., and Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J. Exp. Med. 202 12 (2005) 1623-1626
21. Crowe N.Y., Smyth M.J., and Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196 1 (2002) 119-127
22. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc. Natl. Acad. Sci. U. S. A. 95 10 (1998) 5690-5693
23. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J. Immunol. 166 11 (2001) 6578-6584
24. Nakui M., Ohta A., Sekimoto M., Sato M., Iwakabe K., Yahata T., et al. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin. Exp. Metastasis 18 2 (2000) 147-153
25. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., and Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201 12 (2005) 1973-1985
26. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198 2 (2003) 267-279
27. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171 10 (2003) 5140-5147
28. Liu K., Idoyaga J., Charalambous A., Fujii S., Bonito A., Mordoh J., et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J. Exp. Med. 202 11 (2005) 1507-1516
29. Kawano T., Nakayama T., Kamada N., Kaneko Y., Harada M., Ogura N., et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 59 20 (1999) 5102-5105
30. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167 7 (2001) 4046-4050
31. Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., Kamada N., et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int. J. Cancer 102 2 (2002) 159-165
32. Yanagisawa K., Seino K., Ishikawa Y., Nozue M., Todoroki T., and Fukao K. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J. Immunol. 168 12 (2002) 6494-6499
33. Konishi J., Yamazaki K., Yokouchi H., Shinagawa N., Iwabuchi K., and Nishimura M. The characteristics of human NKT cells in lung cancer-CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum. Immunol. 65 11 (2004) 1377-1388
34. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197 12 (2003) 1667-1676
35. Dhodapkar K.M., Cirignano B., Chamian F., Zagzag D., Miller D.C., Finlay J.L., et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int. J. Cancer 109 6 (2004) 893-899
36. Metelitsa L.S., Wu H.W., Wang H., Yang Y., Warsi Z., Asgharzadeh S., et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199 9 (2004) 1213-1221
37. DelaRosa O., Tarazona R., Casado J.G., Alonso C., Ostos B., Pena J., et al. Valpha24+ NKT cells are decreased in elderly humans. Exp. Gerontol. 37 2-3 (2002) 213-217
38. Sandberg J.K., Bhardwaj N., and Nixon D.F. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur. J. Immunol. 33 3 (2003) 588-596
39. Molling J.W., Kolgen W., van der Vliet H.J., Boomsma M.F., Kruizenga H., Smorenburg C.H., et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116 1 (2005) 87-93
40. Crough T., Purdie D.M., Okai M., Maksoud A., Nieda M., and Nicol A.J. Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br. J. Cancer 91 11 (2004) 1880-1886
41. Peralbo E., DelaRosa O., Gayoso I., Pita M.L., Tarazona R., and Solana R. Decreased frequency and proliferative response of invariant Valpha24Vbeta11 natural killer T (iNKT) cells in healthy elderly. Biogerontology 7 5-6 (2006) 483-492
42. Azuma T., Takahashi T., Kunisato A., Kitamura T., and Hirai H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 63 15 (2003) 4516-4520
43. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9 2 (2003) 606-612
44. Okita R., Saeki T., Takashima S., Yamaguchi Y., and Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol. Rep. 14 5 (2005) 1269-1273
45. Ichihara F., Kono K., Takahashi A., Kawaida H., Sugai H., and Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9 12 (2003) 4404-4408
46. Liyanage U.K., Moore T.T., Joo H.G., Tanaka Y., Herrmann V., Doherty G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169 5 (2002) 2756-2761
47. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2 6 (2002) 389-400
48. Hoffmann T.K., Muller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., and Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 8 6 (2002) 1787-1793
49. van der Vliet H.J., Wang R., Yue S.C., Koon H.B., Balk S.P., and Exley M.A. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J. Immunol. 180 11 (2008) 7287-7293
50. Imataki O., Heike Y., Makiyama H., Iizuka A., Ikarashi Y., Ishida T., et al. Insufficient ex vivo expansion of Valpha24(+) natural killer T cells in malignant lymphoma patients related to the suppressed expression of CD1d molecules on CD14(+) cells. Cytotherapy (2008) 1-10
51. van der Vliet H.J., Pinedo H.M., von Blomberg B.M., van den Eertwegh A.J., Scheper R.J., and Giaccone G. Natural killer T cells. Lancet Oncol. 3 9 (2002) 574
52. van der Vliet H.J., Nishi N., Koezuka Y., von Blomberg B.M., van den Eertwegh A.J., Porcelli S.A., et al. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J. Immunol. Methods 247 1-2 (2001) 61-72
53. Nishi N., van der Vliet H.J., Koezuka Y., von Blomberg B.M., Scheper R.J., Pinedo H.M., et al. Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V alpha 24+V beta 11+ T cells in vitro. Hum. Immunol. 61 4 (2000) 357-365
54. van der Vliet H.J., Molling J.W., Nishi N., Masterson A.J., Kolgen W., Porcelli S.A., et al. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 63 14 (2003) 4101-4106
55. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167 6 (2001) 3114-3122
56. Takahashi T., Nieda M., Koezuka Y., Nicol A., Porcelli S.A., Ishikawa Y., et al. Analysis of human V alpha 24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 164 9 (2000) 4458-4464
57. Chamoto K., Takeshima T., Kosaka A., Tsuji T., Matsuzaki J., Togashi Y., et al. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Immunol. Lett. 95 1 (2004) 5-11
58. Molling J.W., de Gruijl T.D., Glim J., Moreno M., Rozendaal L., Meijer C.J., et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int. J. Cancer 121 8 (2007) 1749-1755
59. Walboomers J.M., Meijer C.J., Steenbergen R.D., van Duin M., Helmerhorst T.J., and Snijders P.J. Human papillomavirus and the development of cervical cancer: concept of carcinogenesis. Ned. Tijdschr. Geneeskd. 144 35 (2000) 1671-1674
60. Molling J.W., Langius J.A., Langendijk J.A., Leemans C.R., Bontkes H.J., van der Vliet H.J., et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25 7 (2007) 862-868
61. Soysal V., Yigitbasi O.G., Alper M., Patiroglu T., and Guney E. Total lymphocyte and T lymphocyte subpopulation levels in head and neck squamous cell carcinomas. J. Exp. Clin. Cancer Res. 17 2 (1998) 207-212
62. Wolf G.T., Bradford C.R., Urba S., Smith A., Eisbruch A., Chepeha D.B., et al. Immune reactivity does not predict chemotherapy response, organ preservation, or survival in advanced laryngeal cancer. Laryngoscope 112 8 Pt 1 (2002) 1351-1356
63. Kuss I., Hathaway B., Ferris R.L., Gooding W., and Whiteside T.L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 10 11 (2004) 3755-3762
64. Schantz S.P., Shillitoe E.J., Brown B., and Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J. Natl. Cancer Inst. 77 4 (1986) 869-875
65. Schantz S.P., and Ordonez N.G. Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer. Nat. Immun. Cell Growth Regul. 10 5 (1991) 278-288
66. Gonzalez F.M., Vargas J.A., Lopez-Cortijo C., Castejon R., Gorriz C., Ramirez-Camacho R., et al. Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch. Otolaryngol Head Neck Surg. 124 8 (1998) 852-856
67. Reichert T.E., Day R., Wagner E.M., and Whiteside T.L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 58 23 (1998) 5344-5347
68. Heimdal J.H., Aarstad H.J., and Olofsson J. Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma. Laryngoscope 110 3 Pt 1 (2000) 402-407
69. Der Vliet H.J., Nishi N., de Gruijl T.D., von Blomberg B.M., van den Eertwegh A.J., Pinedo H.M., et al. Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95 7 (2000) 2440-2442
70. Park S.H., Benlagha K., Lee D., Balish E., and Bendelac A. Unaltered phenotype, tissue distribution and function of Valpha14(+) NKT cells in germ-free mice. Eur. J. Immunol. 30 2 (2000) 620-625
71. Thomas S.Y., Hou R., Boyson J.E., Means T.K., Hess C., Olson D.P., et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J. Immunol. 171 5 (2003) 2571-2580
72. Kim C.H., Johnston B., and Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100 1 (2002) 11-16
73. Apostolou I., Takahama Y., Belmant C., Kawano T., Huerre M., Marchal G., et al. Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc. Natl. Acad. Sci. U. S. A. 96 9 (1999) 5141-5146
74. Kawakami K., Kinjo Y., Uezu K., Yara S., Miyagi K., Koguchi Y., et al. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J. Immunol. 167 11 (2001) 6525-6532
75. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313 18 (1985) 1111-1116
76. Song L., Ara T., Wu H.W., Woo C.W., Reynolds C.P., Seeger R.C., et al. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J. Clin. Invest. 117 9 (2007) 2702-2712
77. Tachibana T., Onodera H., Tsuruyama T., Mori A., Nagayama S., Hiai H., et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11 20 (2005) 7322-7327
78. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 7 (2007) 4
79. Isomoto H., Oka M., Yano Y., Kanazawa Y., Soda H., Terada R., et al. Expression of heat shock protein (Hsp) 70 and Hsp 40 in gastric cancer. Cancer Lett. 198 2 (2003) 219-228
80. Sasaki J., Dejehansart M., and De Bruyn J. The expression of mycobacterial heat shock protein (HSP64) on Meth A tumour cells. Immunol. Cell Biol. 72 5 (1994) 415-418
81. Colgan S.P., Pitman R.S., Nagaishi T., Mizoguchi A., Mizoguchi E., Mayer L.F., et al. Intestinal heat shock protein 110 regulates expression of CD1d on intestinal epithelial cells. J. Clin. Invest. 112 5 (2003) 745-754
82. Nicchitta C.V. Come forth CD1d: Hsp110 in the regulation of intestinal epithelial CD1d expression. J. Clin. Invest. 112 5 (2003) 646-648
83. Bonish B., Jullien D., Dutronc Y., Huang B.B., Modlin R., Spada F.M., et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J. Immunol. 165 7 (2000) 4076-4085
84. Bobryshev Y.V., and Lord R.S. Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J. Vasc. Surg. 35 2 (2002) 368-375
85. Feng H., Zeng Y., Whitesell L., and Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 97 11 (2001) 3505-3512
86. Wu D.Y., Segal N.H., Sidobre S., Kronenberg M., and Chapman P.B. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198 1 (2003) 173-181
87. Lin H., Nieda M., Rozenkov V., and Nicol A.J. Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells, and B cells. Exp. Hematol. 34 3 (2006) 289-295
88. Galli G., Pittoni P., Tonti E., Malzone C., Uematsu Y., Tortoli M., et al. Invariant NKT cells sustain specific B cell responses and memory. Proc. Natl. Acad. Sci. U. S. A. 104 10 (2007) 3984-3989
89. Nishida N., Yano H., Nishida T., Kamura T., and Kojiro M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2 3 (2006) 213-219
90. Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Van Kaer L., Okumura K., et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100 5 (2002) 1728-1733
91. Musha H., Ohtani H., Mizoi T., Kinouchi M., Nakayama T., Shiiba K., et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int. J. Cancer 116 6 (2005) 949-956
92. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 25 (2005) 2654-2666
93. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 5795 (2006) 1960-1964
94. Yue S.C., Shaulov A., Wang R., Balk S.P., and Exley M.A. CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc. Natl. Acad. Sci. U. S. A. 102 33 (2005) 11811-11816
95. Eberl G., Brawand P., and MacDonald H.R. Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. J. Immunol. 165 8 (2000) 4305-4311
96. Gorbachev A.V., and Fairchild R.L. Activated NKT cells increase dendritic cell migration and enhance CD8+ T cell responses in the skin. Eur. J. Immunol. 36 9 (2006) 2494-2503
97. Montoya C.J., Jie H.B., Al Harthi L., Mulder C., Patino P.J., Rugeles M.T., et al. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J. Immunol. 177 2 (2006) 1028-1039
98. Vincent M.S., Leslie D.S., Gumperz J.E., Xiong X., Grant E.P., and Brenner M.B. CD1-dependent dendritic cell instruction. Nat. Immunol. 3 12 (2002) 1163-1168
99. Vuylsteke R.J., Molenkamp B.G., van Leeuwen P.A., Meijer S., Wijnands P.G., Haanen J.B., et al. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin. Cancer Res. 12 9 (2006) 2826-2833
100. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8 12 (2002) 3702-3709
101. Veldt B.J., van der Vliet H.J., von Blomberg B.M., van Vlierberghe H., Gerken G., Nishi N., et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J. Hepatol. 47 3 (2007) 356-365
102. Crowe N.Y., Uldrich A.P., Kyparissoudis K., Hammond K.J., Hayakawa Y., Sidobre S., et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 171 8 (2003) 4020-4027
103. Wilson M.T., Johansson C., Olivares-Villagomez D., Singh A.K., Stanic A.K., Wang C.R., et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. U. S. A. 100 19 (2003) 10913-10918
104. Parekh V.V., Wilson M.T., Olivares-Villagomez D., Singh A.K., Wu L., Wang C.R., et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115 9 (2005) 2572-2583
105. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175 5 (2005) 3092-3101
106. Okai M., Nieda M., Tazbirkova A., Horley D., Kikuchi A., Durrant S., et al. Human peripheral blood Valpha24+ Vbeta11+ NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang. 83 3 (2002) 250-253
107. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 2 (2004) 383-389
108. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201 9 (2005) 1503-1517
109. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11 5 (2005) 1910-1917
110. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12 20 Pt 1 (2006) 6079-6086
111. Uchida T., Horiguchi S., Tanaka Y., Yamamoto H., Kunii N., Motohashi S., et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57 3 (2008) 337-345
112. Masterson A.J., Sombroek C.C., de Gruijl T.D., Graus Y.M., van der Vliet H.J., Lougheed S.M., et al. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 100 2 (2002) 701-703
113. Moreno M., Molling J.W., von Mensdorff-Pouilly S., Hooiberg E., Kramer D., Reurs A.W., et al. Interferon-y producing human invariant natural killer T-cells promote tumor associated antigen-specific cytotoxic T cell responses. J. Immunol. (2008) In press
114. Moreno M., Molling J.W., von Mensdorff-Pouilly S., verheijen R.H., von Blomberg B.M., van den Eertwegh A.J., et al. In vitro expanded human invariant natural killer T-cells enhance functional activity of NK cells. Clin. Immunol. (2008) In press
115. Molling J.W., Moreno M., van der Vliet H.J., von Blomberg B.M., van den Eertwegh A.J., Scheper R.J., et al. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J. Immunol. Methods 322 1-2 (2007) 70-81
116. Maeda M., Lohwasser S., Yamamura T., and Takei F. Regulation of NKT cells by Ly49: analysis of primary NKT cells and generation of NKT cell line. J. Immunol. 167 8 (2001) 4180-4186
117. Ikarashi Y., Iizuka A., Heike Y., Yoshida M., Takaue Y., and Wakasugi H. Cytokine production and migration of in vitro-expanded NK1.1(-) invariant Valpha14 natural killer T (Valpha14i NKT) cells using alpha-galactosylceramide and IL-2. Immunol. Lett. 101 2 (2005) 160-167
118. Gumperz J.E., Roy C., Makowska A., Lum D., Sugita M., Podrebarac T., et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12 2 (2000) 211-221
119. Lantz O., and Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180 3 (1994) 1097-1106
120. Behar S.M., Podrebarac T.A., Roy C.J., Wang C.R., and Brenner M.B. Diverse TCRs recognize murine CD1. J. Immunol. 162 1 (1999) 161-167
121. Molling J.W., Moreno M., de Groot J., van der Vliet H.J., von Blomberg B.M., van den Eertwegh A.J., et al. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunol. Lett. 118 1 (2008) 36-43
122. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202 9 (2005) 1279-1288
123. Shin T., Nakayama T., Akutsu Y., Motohashi S., Shibata Y., Harada M., et al. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14 NKT cells. Int. J. Cancer 91 4 (2001) 523-528
124. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 117 5 (2007) 1195-1203
125. June C.H. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117 5 (2007) 1204-1212
126. Xue S.A., and Stauss H.J. Enhancing immune responses for cancer therapy. Cell Mol. Immunol. 4 3 (2007) 173-184
127. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 100 8 (2003) 4712-4717
128. Ribas A., Camacho L.H., Lopez-Berestein G., Pavlov D., Bulanhagui C.A., Millham R., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23 35 (2005) 8968-8977
129. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23 4 (2005) 741-750
130. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100 14 (2003) 8372-8377
131. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116 2 (2006) 485-494
132. Liu H., Komai-Koma M., Xu D., and Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 103 18 (2006) 7048-7053
133. Barnett B., Kryczek I., Cheng P., Zou W., and Curiel T.J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54 6 (2005) 369-377